tiprankstipranks
Hypera SA (HYPMY)
OTHER OTC:HYPMY
US Market
HYPMY
Hypera SA
RESEARCH TOOLSreports
Want to see HYPMY full AI Analyst Report?

Hypera SA (HYPMY) Earnings Dates, Call Summary & Reports

9 Followers

Earnings Data

Report Date
Aug 06, 2026
After Close (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
―
Last Year’s EPS
0.12
Same Quarter Last Year
Analyst Consensus
―
Based on 0 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Oct 28, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including strong revenue growth, successful working capital optimization, and record operational cash flow. However, challenges were noted in the institutional market and R&D approval delays. Despite these challenges, the overall performance and strategic initiatives indicate a positive outlook.
Company Guidance
In the third quarter of 2025, Hypera Pharma demonstrated strong financial and operational performance, driven by strategic initiatives and market dynamics. The company successfully completed its working capital optimization process, which led to a significant improvement in operational cash generation without affecting sell-out or profitability. Sell-out increased by nearly 2 percentage points above the market and 3 percentage points above the growth in the second quarter, with particular strength in influenza medication, pain killers, and skincare products. Hypera maintained its operational profitability with an EBITDA of approximately BRL 760 million and a 34% margin, which was an improvement over previous quarters. Net revenue grew by 16% to BRL 2.2 billion, despite a 4% reduction in the institutional market, attributed to lower public market sales. The company's gross margins stood at 61.2%, and they reported a reduced investment in working capital, which now represents 30% of net revenue, down from previous years. Hypera also approved BRL 185 million in shareholder payments and strengthened its corporate governance. Looking ahead, the company plans to leverage its strong brand portfolio and innovation pipeline, with significant opportunities expected from the expiration of the semaglutide patent and other molecules.
Successful Working Capital Optimization
The company successfully concluded its working capital optimization process, leading to improved operational cash generation without impacting sell-out or profitability.
Strong Revenue Growth
Net revenue increased by 16% to BRL 2.2 billion, driven by sell-out growth in retail, despite a 4% reduction in the institutional market.
High EBITDA Margin
Maintained an operational EBITDA margin of 34%, reaching nearly BRL 760 million, which is higher than previous quarters.
Record Operational Cash Flow
Achieved the highest operational cash flow in the company's history, with total cash generation of BRL 630 million, reducing net debt to 2.4x annualized EBITDA.
Strategic Product Launches
Focused on new product launches and market share gains, particularly in influenza medication, pain killers, gastric, cardiology, skin care, and hydration.

Hypera SA (HYPMY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

HYPMY Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 06, 2026
2026 (Q2)
- / -
0.118―――
Apr 28, 2026
2026 (Q1)
- / 0.10
-0.038373.68% (+0.14)
Mar 12, 2026
2025 (Q4)
- / 0.13
0.021523.81% (+0.11)
Oct 28, 2025
2025 (Q3)
- / 0.13
0.10623.58% (+0.03)
Aug 06, 2025
2025 (Q2)
- / 0.12
0.148-20.27% (-0.03)
Apr 23, 2025
2025 (Q1)
- / -0.04
0.125-130.40% (-0.16)
Mar 20, 2025
2024 (Q4)
- / 0.02
0.097-78.35% (-0.08)
Nov 13, 2024
2024 (Q3)
- / 0.11
0.16-33.75% (-0.05)
Jul 25, 2024
2024 (Q2)
- / 0.15
0.159-6.92% (-0.01)
Apr 26, 2024
2024 (Q1)
- / 0.12
0.10221.57% (+0.02)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

HYPMY Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 28, 2026
$4.41$4.52+2.47%
Mar 12, 2026
$4.06$4.02-1.06%
Oct 28, 2025
$4.25$4.43+4.29%
Aug 06, 2025
$4.41$4.26-3.36%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Hypera SA (HYPMY) report earnings?
Hypera SA (HYPMY) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
    What is Hypera SA (HYPMY) earnings time?
    Hypera SA (HYPMY) earnings time is at Aug 06, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is HYPMY EPS forecast?
          Currently, no data Available